Molecular basis of gain-of-function LEOPARD syndrome-associated SHP2 mutations

Zhi Hong Yu, Ruo Yu Zhang, Chad D. Walls, Lan Chen, Sheng Zhang, Li Wu, Sijiu Liu, Zhong Yin Zhang

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

The Src homology 2 (SH2) domain-containing protein tyrosine phosphatase 2 (SHP2) is a critical signal transducer downstream of growth factors that promotes the activation of the RAS-ERK1/2 cascade. In its basal state, SHP2 exists in an autoinhibited closed conformation because of an intramolecular interaction between its N-SH2 and protein tyrosine phosphatase (PTP) domains. Binding to pTyr ligands present on growth factor receptors and adaptor proteins with its N-SH2 domain localizes SHP2 to its substrates and frees the active site from allosteric inhibition. Germline mutations in SHP2 are known to cause both Noonan syndrome (NS) and LEOPARD syndrome (LS), two clinically similar autosomal dominant developmental disorders. NS-associated SHP2 mutants display elevated phosphatase activity, while LS-associated SHP2 mutants exhibit reduced catalytic activity. A conundrum in how clinically similar diseases result from mutations to SHP2 that have opposite effects on this enzyme's catalytic functionality exists. Here we report a comprehensive investigation of the kinetic, structural, dynamic, and biochemical signaling properties of the wild type as well as all reported LS-associated SHP2 mutants. The results reveal that LS-causing mutations not only affect SHP2 phosphatase activity but also induce a weakening of the intramolecular interaction between the N-SH2 and PTP domains, leading to mutants that are more readily activated by competing pTyr ligands. Our data also indicate that the residual phosphatase activity associated with the LS SHP2 mutant is required for enhanced ERK1/2 activation. Consequently, catalytically impaired SHP2 mutants could display gain-of-function properties because of their ability to localize to the vicinity of substrates for longer periods of time, thereby affording the opportunity for prolonged substrate turnover and sustained RAS-ERK1/2 activation.

Original languageEnglish (US)
Pages (from-to)4136-4151
Number of pages16
JournalBiochemistry
Volume53
Issue number25
DOIs
StatePublished - Jul 1 2014

Fingerprint

LEOPARD Syndrome
Protein Tyrosine Phosphatases
Chemical activation
Phosphoric Monoester Hydrolases
Mutation
Noonan Syndrome
Non-Receptor Type 11 Protein Tyrosine Phosphatase
Substrates
Ligands
Growth Factor Receptors
Structural dynamics
SH2 Domain-Containing Protein Tyrosine Phosphatases
Conformations
Transducers
Catalyst activity
Intercellular Signaling Peptides and Proteins
Protein Phosphatase 2
src Homology Domains
Germ-Line Mutation
Kinetics

ASJC Scopus subject areas

  • Biochemistry

Cite this

Yu, Z. H., Zhang, R. Y., Walls, C. D., Chen, L., Zhang, S., Wu, L., ... Zhang, Z. Y. (2014). Molecular basis of gain-of-function LEOPARD syndrome-associated SHP2 mutations. Biochemistry, 53(25), 4136-4151. https://doi.org/10.1021/bi5002695

Molecular basis of gain-of-function LEOPARD syndrome-associated SHP2 mutations. / Yu, Zhi Hong; Zhang, Ruo Yu; Walls, Chad D.; Chen, Lan; Zhang, Sheng; Wu, Li; Liu, Sijiu; Zhang, Zhong Yin.

In: Biochemistry, Vol. 53, No. 25, 01.07.2014, p. 4136-4151.

Research output: Contribution to journalArticle

Yu, ZH, Zhang, RY, Walls, CD, Chen, L, Zhang, S, Wu, L, Liu, S & Zhang, ZY 2014, 'Molecular basis of gain-of-function LEOPARD syndrome-associated SHP2 mutations', Biochemistry, vol. 53, no. 25, pp. 4136-4151. https://doi.org/10.1021/bi5002695
Yu ZH, Zhang RY, Walls CD, Chen L, Zhang S, Wu L et al. Molecular basis of gain-of-function LEOPARD syndrome-associated SHP2 mutations. Biochemistry. 2014 Jul 1;53(25):4136-4151. https://doi.org/10.1021/bi5002695
Yu, Zhi Hong ; Zhang, Ruo Yu ; Walls, Chad D. ; Chen, Lan ; Zhang, Sheng ; Wu, Li ; Liu, Sijiu ; Zhang, Zhong Yin. / Molecular basis of gain-of-function LEOPARD syndrome-associated SHP2 mutations. In: Biochemistry. 2014 ; Vol. 53, No. 25. pp. 4136-4151.
@article{934bf5d9b41a47f48f6eff1763931aa7,
title = "Molecular basis of gain-of-function LEOPARD syndrome-associated SHP2 mutations",
abstract = "The Src homology 2 (SH2) domain-containing protein tyrosine phosphatase 2 (SHP2) is a critical signal transducer downstream of growth factors that promotes the activation of the RAS-ERK1/2 cascade. In its basal state, SHP2 exists in an autoinhibited closed conformation because of an intramolecular interaction between its N-SH2 and protein tyrosine phosphatase (PTP) domains. Binding to pTyr ligands present on growth factor receptors and adaptor proteins with its N-SH2 domain localizes SHP2 to its substrates and frees the active site from allosteric inhibition. Germline mutations in SHP2 are known to cause both Noonan syndrome (NS) and LEOPARD syndrome (LS), two clinically similar autosomal dominant developmental disorders. NS-associated SHP2 mutants display elevated phosphatase activity, while LS-associated SHP2 mutants exhibit reduced catalytic activity. A conundrum in how clinically similar diseases result from mutations to SHP2 that have opposite effects on this enzyme's catalytic functionality exists. Here we report a comprehensive investigation of the kinetic, structural, dynamic, and biochemical signaling properties of the wild type as well as all reported LS-associated SHP2 mutants. The results reveal that LS-causing mutations not only affect SHP2 phosphatase activity but also induce a weakening of the intramolecular interaction between the N-SH2 and PTP domains, leading to mutants that are more readily activated by competing pTyr ligands. Our data also indicate that the residual phosphatase activity associated with the LS SHP2 mutant is required for enhanced ERK1/2 activation. Consequently, catalytically impaired SHP2 mutants could display gain-of-function properties because of their ability to localize to the vicinity of substrates for longer periods of time, thereby affording the opportunity for prolonged substrate turnover and sustained RAS-ERK1/2 activation.",
author = "Yu, {Zhi Hong} and Zhang, {Ruo Yu} and Walls, {Chad D.} and Lan Chen and Sheng Zhang and Li Wu and Sijiu Liu and Zhang, {Zhong Yin}",
year = "2014",
month = "7",
day = "1",
doi = "10.1021/bi5002695",
language = "English (US)",
volume = "53",
pages = "4136--4151",
journal = "Biochemistry",
issn = "0006-2960",
publisher = "American Chemical Society",
number = "25",

}

TY - JOUR

T1 - Molecular basis of gain-of-function LEOPARD syndrome-associated SHP2 mutations

AU - Yu, Zhi Hong

AU - Zhang, Ruo Yu

AU - Walls, Chad D.

AU - Chen, Lan

AU - Zhang, Sheng

AU - Wu, Li

AU - Liu, Sijiu

AU - Zhang, Zhong Yin

PY - 2014/7/1

Y1 - 2014/7/1

N2 - The Src homology 2 (SH2) domain-containing protein tyrosine phosphatase 2 (SHP2) is a critical signal transducer downstream of growth factors that promotes the activation of the RAS-ERK1/2 cascade. In its basal state, SHP2 exists in an autoinhibited closed conformation because of an intramolecular interaction between its N-SH2 and protein tyrosine phosphatase (PTP) domains. Binding to pTyr ligands present on growth factor receptors and adaptor proteins with its N-SH2 domain localizes SHP2 to its substrates and frees the active site from allosteric inhibition. Germline mutations in SHP2 are known to cause both Noonan syndrome (NS) and LEOPARD syndrome (LS), two clinically similar autosomal dominant developmental disorders. NS-associated SHP2 mutants display elevated phosphatase activity, while LS-associated SHP2 mutants exhibit reduced catalytic activity. A conundrum in how clinically similar diseases result from mutations to SHP2 that have opposite effects on this enzyme's catalytic functionality exists. Here we report a comprehensive investigation of the kinetic, structural, dynamic, and biochemical signaling properties of the wild type as well as all reported LS-associated SHP2 mutants. The results reveal that LS-causing mutations not only affect SHP2 phosphatase activity but also induce a weakening of the intramolecular interaction between the N-SH2 and PTP domains, leading to mutants that are more readily activated by competing pTyr ligands. Our data also indicate that the residual phosphatase activity associated with the LS SHP2 mutant is required for enhanced ERK1/2 activation. Consequently, catalytically impaired SHP2 mutants could display gain-of-function properties because of their ability to localize to the vicinity of substrates for longer periods of time, thereby affording the opportunity for prolonged substrate turnover and sustained RAS-ERK1/2 activation.

AB - The Src homology 2 (SH2) domain-containing protein tyrosine phosphatase 2 (SHP2) is a critical signal transducer downstream of growth factors that promotes the activation of the RAS-ERK1/2 cascade. In its basal state, SHP2 exists in an autoinhibited closed conformation because of an intramolecular interaction between its N-SH2 and protein tyrosine phosphatase (PTP) domains. Binding to pTyr ligands present on growth factor receptors and adaptor proteins with its N-SH2 domain localizes SHP2 to its substrates and frees the active site from allosteric inhibition. Germline mutations in SHP2 are known to cause both Noonan syndrome (NS) and LEOPARD syndrome (LS), two clinically similar autosomal dominant developmental disorders. NS-associated SHP2 mutants display elevated phosphatase activity, while LS-associated SHP2 mutants exhibit reduced catalytic activity. A conundrum in how clinically similar diseases result from mutations to SHP2 that have opposite effects on this enzyme's catalytic functionality exists. Here we report a comprehensive investigation of the kinetic, structural, dynamic, and biochemical signaling properties of the wild type as well as all reported LS-associated SHP2 mutants. The results reveal that LS-causing mutations not only affect SHP2 phosphatase activity but also induce a weakening of the intramolecular interaction between the N-SH2 and PTP domains, leading to mutants that are more readily activated by competing pTyr ligands. Our data also indicate that the residual phosphatase activity associated with the LS SHP2 mutant is required for enhanced ERK1/2 activation. Consequently, catalytically impaired SHP2 mutants could display gain-of-function properties because of their ability to localize to the vicinity of substrates for longer periods of time, thereby affording the opportunity for prolonged substrate turnover and sustained RAS-ERK1/2 activation.

UR - http://www.scopus.com/inward/record.url?scp=84903703387&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903703387&partnerID=8YFLogxK

U2 - 10.1021/bi5002695

DO - 10.1021/bi5002695

M3 - Article

C2 - 24935154

AN - SCOPUS:84903703387

VL - 53

SP - 4136

EP - 4151

JO - Biochemistry

JF - Biochemistry

SN - 0006-2960

IS - 25

ER -